Business
Voyager Reports First Quarter 2025 Financial and Operating Results
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – Recent Voyager data on VY7523 and VY1706 presented at AD/PD™ 2025 continue to support tau as next critical target in Alzheimer’s disease – LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurol
About this update from Voyager Therapeutics, Inc.
[{"type":"image","alt":"Voyager Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Voyager Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/1842388f47778127775e1c1d222cee9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aA28rCi8Vnw73esVg7Kfbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1842388f47778127775e1c1d222cee9a","width":300,"height":300}},"lazy":false},{"type":"text","content":"– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg –","length":197,"tagName":"p"},{"type":"text","content":"– Recent Voyager data on VY7523 and VY1706 presented at AD/PD™ 2025 continue to support tau as next critical target in Alzheimer’s disease –","length":150,"tagName":"p"},{"type":"text","content":"LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported first quarter 2025 financial and operating results.","length":249,"tagName":"p"},{"type":"text","content":"“Voyager ended the first quarter of 2025 with a strong cash position of $295 million, which we expect to provide runway into mid-2027. This runway guidance does not include potential milestone payments from existing partnerships, such as the up to $35 million we could earn in 2025-2026 from the Neurocrine-partnered FA and GBA1 programs,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “We continue to thoughtfully and strategically advance our pipeline, including our two wholly-owned tau targeting programs VY7523 and VY1706 for Alzheimer’s disease, as well as the FA and GBA1 programs, which are advancing towards INDs this year.”","length":666,"tagName":"p"},{"type":"text","content":"First Quarter 2025 and Recent Highlights","length":40,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Neurocrine partnership update: Neurocrine continues to expect investigational new drug (IND) submissions in 2025 for the Friedreich’s ataxia (FA) and GBA1 gene therapy programs, provided the ongoing GLP toxicology...